IP Library Granted Patent US 11,466,095
Granted Patent B2
US 11,466,095 · App. 16/221,747 · Granted Oct 11, 2022

CD37-binding molecules and immunoconjugates thereof

Inventors: Jutta Deckert (Lexington, MA); Peter Park (Somerville, MA); Daniel Tavares (Natick, MA); Lingyun Rui (Weston, MA)
C07K16/2896A61K47/60A61K47/6803A61K47/6817A61K47/6849A61K47/6867C07K16/30G01N33/566A61K2039/505C07K2317/24C07K2317/33C07K2317/56C07K2317/565C07K2317/60C07K2317/73C07K2317/732C07K2317/734C07K2317/92G01N2333/70596
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,466,095
App. No.
16/221,747
Granted
Oct 11, 2022
Kind
B2
Abstract

Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.

Claims (21)

1. An isolated polynucleotide comprising a first nucleic acid sequence that encodes a variable heavy region comprising the polypeptide sequence of SEQ ID NO:57 and a second nucleic acid sequence that encodes a variable light region comprising the polypeptide sequence of SEQ ID NO:74.

2. The isolated polynucleotide of claim 1 , wherein the first nucleic acid sequence encodes a heavy chain comprising the polypeptide sequence of SEQ ID NO:90.

3. The isolated polynucleotide of claim 1 , wherein the first nucleic acid sequence comprises the sequence of SEQ ID NO:123.

4. The isolated polynucleotide claim 2 , wherein the first nucleic acid sequence comprises the sequence of SEQ ID NO:153.

5. A vector comprising the polynucleotide of claim 1 .

6. A host cell comprising the vector of claim 5 .

7. The host cell of claim 6 , wherein the host cell is a Chinese Hamster Ovary (CHO) cell.

8. The host cell of claim 6 , wherein the host cell is a Human Embryonic Kidney-293 (HEK-293) cell.

9. The isolated polynucleotide of claim 2 , wherein the second nucleic acid sequence encodes a light chain comprising the polypeptide sequence of SEQ ID NO:107.

10. The isolated polynucleotide of claim 3 , wherein the second nucleic acid sequence comprises the sequence of SEQ ID NO:138.

11. The isolated polynucleotide claim 9 , wherein the second nucleic acid sequence comprises the sequence of SEQ ID NO:163.

12. A vector comprising the polynucleotide of claim 9 .

13. A host cell comprising the vector of claim 12 .

14. The host cell of claim 13 , wherein the host cell is a CHO cell.

15. The host cell of claim 13 , wherein the host cell is a HEK-293 cell.

16. A host cell comprising a nucleic acid sequence encoding a variable heavy chain region and a nucleic acid sequence encoding a variable light chain region; wherein the nucleic acid sequence encoding the variable heavy chain region and the nucleic acid sequence encoding the variable light chain region encode the polypeptide sequences of SEQ ID NOs:57 and 74.

17. The host cell of claim 16 , wherein the nucleic acid sequence encoding the variable heavy chain region encodes a heavy chain, wherein the nucleic acid sequence encoding the variable light chain region encodes a light chain, and wherein the heavy chain and the light chain comprise the polypeptide sequences of SEQ ID NOs:90 and 107.

18. The host cell of claim 16 , wherein the nucleic acid sequence encoding the variable heavy chain region and the nucleic acid sequence encoding the variable light chain region comprise the sequences of SEQ ID NOs:123 and 138.

19. The host cell of claim 17 , wherein the nucleic acid sequence encoding the heavy chain and the nucleic acid sequence encoding the light chain comprise the sequences of SEQ ID NOs:153 and 163.

20. The host cell of claim 16 , wherein the host cell is a CHO cell.

21. The host cell of claim 16 , wherein the host cell is a HEK-293 cell.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2019
From: DECKERT, JUTTA; PARK, PETER; TAVARES, DANIEL; RUI, LINGYUN
To: IMMUNOGEN, INC.
Reel/Frame 048776/0144 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2019
From: IMMUNOGEN, INC.
To: DEBIOPHARM INTERNATIONAL, S.A.
Reel/Frame 048776/0147 →
Continuity (7)
Division 15130667 · Apr 15, 2016
Division 13796768 · Mar 12, 2013
Division 13045693 · Mar 11, 2011
Provisional Application 61412644 · Nov 11, 2010
Provisional Application 61327314 · Apr 23, 2010
Provisional Application 61313628 · Mar 12, 2010
Related Publication 20190218303A1 · Jul 18, 2019
Cited By (2)
US 12,239,732 US 12,559,566